Entire Transcript in Adobe Acrobat Format - National Reference ...

239
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
not going to work. So then we are going to step back --
these research advance directives are going to be general
things not made with the specific researcher who is going
to do your experiment at all and they are going to become,
you know, some kind of carte blanche.
DR. CASSELL: Mr. Chairman, could I ask for
clarification?
DR. DUMAS: Wrong, no. No.
MR. CAPRON: Wrong.
DR. CASSELL: I just want to clarify the
question we are discussing.
DR. CHILDRESS: Use the microphone.
DR. CASSELL: I take it that we have made a
change in therapeutic research even where risk is present,
that the family, for example, or a representative can now
consent whereas before that was not the case, I mean, in
previous lifetimes that was not the case. We put that in.
We have added the family or legally appointed
representative. Now we are arguing only about one area,
nontherapeutic risky research. That is the only thing we
are discussing.
DR. CHILDRESS: Greater than minimal risk,
nonpotentially beneficial research.
DR. CASSELL: Right. But we have as a